Abiraterone decanoate

DB18905InvestigationalSmall moleculeCytochrome P450 17A1 Inhibitors

Abiraterone decanoate is under investigation in clinical trial NCT04729114 (Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer).

Mechanism: Pharmacologically active on Androgen receptor
Curator reviewed
Formula / weight: C₃₄H₄₉NO₂ · 503.771 g/mol (avg)
Code names: ASP5541 · PRL-02

Resolves to

Compound

UNIIU6XMS339F5CAS2486052-18-8

Structure

InChIKeyXPCSGTPPHYORKJ-YHXMLEJGSA-NSMILES[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCCCCC

Targets

P10275AR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Abiraterone decanoate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account